GNX201-ADC is GlycoNex's next-generation pro-antibody antibody-drug conjugate, targeting a tumor-associated carbohydrate antigen (specific target identity withheld under partnership terms). The candidate combines GlycoNex's proprietary anti-glycan antibody with antibody lock technology in-licensed from Precisemab in May 2024 — the antibody remains masked during systemic circulation and is selectively activated by elevated protease activity in the tumor microenvironment, expanding the therapeutic window for ADC therapy in solid tumors. Preclinical proof-of-concept has been completed across multiple cancer models, with results published in the International Journal of Biological Macromolecules (Impact Factor 8.5). GNX201-ADC is co-developed with Nippon Kayaku Co., Ltd. of Japan under a March 2026 partnership; the program is in Lead Optimization, with IND submission targeted for 2028.
GNX201-ADC
Pro-Antibody Antibody-Drug Conjugate for Solid Tumors
Overview
Mechanism of Action
Masked antibody circulates
Antibody lock shields the antibody's binding domain during systemic circulation, reducing healthy-tissue exposure.
TME protease activates
Elevated tumor-microenvironment protease activity selectively cleaves the lock, unmasking the antibody.
Glycan engagement & payload delivery
Unmasked antibody binds the tumor-associated glycan antigen; ADC is internalized and delivers payload to the tumor cell.
Conventional ADCs face a persistent trade-off: increasing payload potency widens the efficacy margin but narrows the therapeutic window through off-target toxicity. Pro-antibody designs address this trade-off architecturally rather than chemically — the antibody itself is kept inactive in circulation and unmasked only by the protease environment characteristic of solid tumors.
By combining a glycan-targeted antibody (drawn from GlycoNex's GlycoSH library) with antibody lock technology, GNX201-ADC pursues a dual selectivity profile: tumor selectivity at the antigen level (glycan vs. protein targets) compounded with tumor selectivity at the activation level (protease-gated unmasking). The result is a candidate designed for an expanded therapeutic window in solid tumors with significant unmet medical need.
Indications & Therapeutic Strategy
GNX201-ADC pursues solid tumors with significant unmet medical need, leveraging tumor-microenvironment-selective activation of a glycan-targeted ADC. Rather than tying the program to a single oncology indication at this stage, GlycoNex is developing GNX201-ADC as a broad solid-tumor candidate — specific indication focus will be refined upon completion of preclinical efficacy and biomarker studies in collaboration with Nippon Kayaku. This breadth reflects the broad expression pattern of the underlying glycan antigen across multiple epithelial tumor types.
Development Timeline
-
Antibody lock technology in-licensed
In-licensed antibody lock technology from Precisemab of Taiwan, providing the molecular architecture for GNX201-ADC's pro-antibody design.
-
Preclinical proof-of-concept established
Across multiple cancer models, GNX201-ADC demonstrated tumor-selective activation and antitumor activity.
-
Published in IJBM (IF 8.5)
Preclinical efficacy and selectivity data published in the International Journal of Biological Macromolecules.
-
Nippon Kayaku co-development signed Milestone
GlycoNex and Nippon Kayaku entered a co-development agreement; GlycoNex leads antibody and preclinical work, Nippon Kayaku contributes clinical trial strategy.
-
IND submission targeted
Investigational New Drug application planned, contingent on completion of Lead Optimization and IND-enabling studies.
Why GNX201-ADC Stands Out
Pro-antibody architectural selectivity
Antibody lock keeps the binding domain inactive in systemic circulation; selective unmasking by tumor-microenvironment proteases creates a wider therapeutic window than conventional ADC designs achieve through linker chemistry alone.
GlycoSH-derived antibody origin
Built on GlycoNex's proprietary anti-glycan antibody library, accumulated over more than two decades of dedicated glycobiology research at GlycoNex's New Taipei City laboratories.
Peer-reviewed preclinical evidence
Preclinical efficacy and selectivity data published in the International Journal of Biological Macromolecules (Impact Factor 8.5), supporting the candidate's mechanism.
Japan co-development partner
Nippon Kayaku Co., Ltd. brings established clinical trial strategy and operational expertise from the Japanese oncology market, enabling efficient Japan-anchored development.
Partnership with Nippon Kayaku
In March 2026, GlycoNex entered a co-development agreement with Nippon Kayaku Co., Ltd. for the GNX201-ADC program. Under the agreement, GlycoNex leads antibody discovery and preclinical ADC development, while Nippon Kayaku contributes clinical trial strategy and operational expertise. GlycoNex's contribution to the partnership rests on more than two decades of antibody drug development experience and its proprietary anti-glycan antibody library — capabilities aligned with one of the most actively developed therapeutic modalities in oncology today.
Co-development work split
| Workstream | Lead |
|---|---|
| Antibody discovery & development | GlycoNex |
| ADC technology evaluation & preclinical leadership | GlycoNex |
| Clinical trial strategy & operational expertise | Nippon Kayaku |
Beyond the existing Nippon Kayaku co-development, GNX201-ADC remains available for licensing as a discrete product. Inquiries are welcomed from companies bringing complementary clinical, regulatory, or commercial capabilities in solid-tumor ADCs.
References
- International Journal of Biological Macromolecules — preclinical efficacy publication (Impact Factor 8.5)
- PR Newswire — Nippon Kayaku co-development announcement,
- Patent applications — PCT/US25/54391; US 19/381,904; TW 114143162 (prosecution in progress)
- Taiwan TWSE Material Information Disclosure — TWSE 4168
Partner with us on GNX201-ADC
Available for licensing as a discrete product, alongside the ongoing co-development with Nippon Kayaku. We welcome discussions with companies bringing complementary clinical, regulatory, or commercial capabilities in solid-tumor ADCs.